Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M1,531Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-0.0EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)23.8Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.610-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %1.7PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M14,350,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with IXJ

Number of guru portfolios checked: 68.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

IXJ is held by these investors:

IXJ: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.481025.42view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94529.81view
Dinwoodie, Tyler Wayne PaulSenior Officer 2017-01-16Buy4,000$0.1762658.82view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.367744.85view
Bebek, IvanDirector 2017-01-16Buy8,990$3.383056.51view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4125921.95view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91282.26view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.271601.59view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.3876.7view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1571026.67view

Quarterly/Annual Reports about IXJ:

    News about IXJ:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    AstraZeneca’s Segment-by-Segment Performance in 1Q17 May 29 2017
    Performance of Merck’s Animal Health Segment in 1Q17 May 25 2017
    Allergan’s 1Q17 Earnings: Analysts’ Estimates May 08 2017
    Pfizer’s Geographical Performance in 1Q17 May 05 2017
    GlaxoSmithKline’s 1Q17 Estimates: Consumer Healthcare Apr 26 2017
    What Analysts Expect of Bristol-Myers Squibb’s 1Q17 Earnings Apr 25 2017
    Novartis’s 1Q17 Estimates for Sandoz Apr 24 2017
    Johnson & Johnson’s Revenue Estimates: Expect Growth! Apr 13 2017
    Examining Gilead Sciences’ 1Q17 Performance Apr 10 2017
    Assessing Johnson & Johnson’s 1Q17 Performance Apr 07 2017
    Must-Know Corporate and Pipeline Developments for Pfizer Apr 05 2017
    How Eli Lilly’s New Products Performed in 2016 Apr 03 2017
    Johnson & Johnson’s Pharmaceuticals Segment Mar 14 2017
    How Gilead’s Other Products Fared in 2016 Mar 02 2017
    Strong Performance of AstraZeneca’s Brilinta and Farxiga in 2016 Feb 28 2017
    Pfizer’s Valuation after Its 4Q16 Earnings Release Feb 24 2017
    Eli Lilly & Co.’s Endocrine Franchise Feb 24 2017
    Analyzing Merck & Co.’s Revenue Estimates in 4Q16 Jan 31 2017
    Opdivo: Bristol-Myers Squibb’s Blockbuster Oncology Drug Jan 31 2017
    Exploring JNJ’s 2017 Profitability and Financial Guidance Jan 30 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)